The Director and Senior Advisor and member of the board of directors of the MAScIR Foundation (Moroccan Foundation for Advanced Science, Innovation and Research), Dr. Hassan Sefrioui, has been appointed member of the DTAG (Diagnostic and Technical Advisory Group) of the World Organization of Health (WHO) for the period 2021-2023.
Dr. Sefrioui will bring his expertise in the development and production of diagnostic tests, their clinical validation as well as the corresponding regulatory aspects, indicates a statement from MAScIR. DTAG was created by WHO in response to the urgent need for new and improved diagnostic tools for specific infectious diseases. Indeed, the DTAG and its cross-cutting working groups will help WHO to review and prioritize diagnostic needs, define use cases and target product profiles (PPTs) and facilitate the development and validation of tests, the statement said.
Dr. Sefrioui has over 20 years of research and development (R&D) experience in industry and academia. He holds a doctorate in medical sciences from the University of Louvain in Belgium and worked as a post-doc at the University of San Diego in California. Subsequently, he served for 10 years as director in the biotechnology industry sector in Europe, notably at TIGENIX, a subsidiary of the multinational TAKEDA. In 2010, Dr. Sefrioui joined the MAScIR Foundation as director of the Center for Medical Biotechnology. Based on its 10 years of expertise in the field of diagnostics, the team under its responsibility has developed the first Moroccan diagnostic kits that target several diseases including breast cancer, leukemia, tuberculosis, hepatitis C and recently the Covid-19.
As a reminder, the MAScIR Foundation’s medical biotechnology research center was designated in 2015 as an African center of excellence in cancer and infectious disease diagnostics, by the ANDI (African Network for Drugs & Diagnostics Innovations).